Arixon 500 mg/vial (IM Injection)
Medicine Details
| Category | Details |
|---|---|
| Generic | Ceftriaxone sodium |
| Company | Beximco pharmaceuticals ltd |
| Also available as |
Indications
- Lower respiratory tract infections
- Acute Bacterial Otitis Media
- Skin and skin structure infections
- Urinary tract infections
- Gonorrhea
- Bacterial Septicemia
- Bone and joint infections
- Meningitis
- Prevention of postoperative infections
- Perioperative prophylaxis of infections associated with surgery
Pharmacology
Ceftriaxone is a 3rd generation broad-spectrum parenteral cephalosporin antibiotic. It has potent bactericidal activity against a wide range of Gram-positive and Gram-negative organisms. Like other cephalosporins and penicillins, Ceftriaxone kills bacteria by interfering with the synthesis of the bacterial cell wall. Ceftriaxone has a high degree of stability in the presence of beta lactamases. The drug is highly protein bound (95%).
Dosage
- 1 to 2 gm by intravenous or intramuscular administration once a day (or in equally divided doses twice a day)
- 50 to 75 mg/kg intravenous or intramuscular administration once a day (or in equally divided doses twice a day) for infants and children (01 month or older)
Administration
- Intramuscular Injection: 250 mg or 500 mg Ceftriaxone should be dissolved in 2 ml Lidocaine HCI 1% injection or 1 g Ceftriaxone in 3.5 ml of Lidocaine HCI 1% injection
- Intravenous Injection: 250 mg or 500 mg Ceftriaxone should be dissolved in 5 ml of Water for injection or 1 g Ceftriaxone in 10 ml of Water for injection USP or 2 g Ceftriaxone in 20 ml of Water for injection
- The injection should be administered over 2-4 minutes, by Intramuscular or Intravenous injection or by tubing infusion over a period of 30 minutes at concentration between 10 mg/mL and 40 mg/mL
Interaction
No drug interactions have been reported.
Contraindications
Ceftriaxone should not be given to patients with a history of hypersensitivity to cephalosporin antibiotics.
Side Effects
- Gastro-intestinal effects including diarrhea, nausea and vomiting, stomatitis and glossitis
- Cutaneous reactions including rash, pruritus, urticaria, edema and erythema multiforme
- Hematologic reactions including eosinophilia, thrombocytopenia, leucopenia, anemia and neutropenia
- Hepatic reactions including elevations of SGOT or SGPT, bilirubinemia
- CNS reactions including nervousness, confusion, sleep disturbances, headache, hyperactivity, convulsion, hypertonia and dizziness
- Local phlebitis occurs rarely following intravenous administration
Pregnancy & Lactation
Its safety in human pregnancy has not been established. Therefore, it should not be used in pregnancy unless absolutely indicated. Caution should be exercised when Ceftriaxone is administered to a lactating mother.
Precautions & Warnings
- Anaphylactic shock cannot be ruled out
- Shadows suggesting sludge have been detected by sonograms of the gallbladder in rare cases
- Blood picture should be checked at regular intervals during prolonged treatment
Use in Special Populations
Arixon must not be given to neonates if the neonate is premature and newborn (up to 28 days of age)
Overdose Effects
There is no specific antidote. Treatment of overdosage should be symptomatic
Therapeutic Class
Third generation Cephalosporins
Storage Conditions
Vial store in a cool, dry place (below 30° C), away from light & moisture. Keep out of the reach of children